&lt;p&gt;Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients&lt;/p&gt;

Almalag, Haya M.; Abouzaid, Hanan H; Alnaim, Lamya; Albaqami, Jawza; Alshalhoub, Rawan; Almaghlouth, Ibrahim; Dessougi, Maha; Harthi, Amal Al; Bedaiwi, Mohamed; Alfi, Eman; Omair, Mohammed A.

doi:10.2147/oarrr.s263287

Cited by 14 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is widely used as a routine laboratory test for RA diagnosis in clinical practice. [ 19 ] In the present study, anti-CCP was detected in 47 (78.3%) patients, and these findings were inconsistent with investigations conducted by Omair (98.3%)[ 18 ] or Attar (57.2%). [ 16 ]…”

Section: Discussioncontrasting

confidence: 99%

“…The percentage of patients with a positive RF (66.7%) was comparable to that found in Attar's study (65%). [ 16 ] However, a substantially higher number of patients were observed to have positive RF in research conducted by Omair (93.2%),[ 18 ] Alballa (79.5%),[ 8 ] and Al-Bishri et al . (76.1%),[ 9 ] however; a smaller number was presented in the Attar's study (54%).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, both markers were positive in 59.6% of the female patients among the studied groups and comparable with those of another study. [ 18 ]…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Profile and Comorbidities Associated with Rheumatoid Arthritis Patients in Sudair, Saudi Arabia

Alanazi

2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic, debilitating condition that has a significant effect on the lives of patients, their families, and society at large. Aims: The aim is to determine the clinical profile and any comorbidities associated with RA patients in the Sudair region of Saudi Arabia. Subjects and Methods: Sixty patients were included in this cross-sectional observational study, both newly or already diagnosed with RA, fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for RA. They were followed up in the rheumatology clinic in King Khalid Majmaah Hospital in the Majmaah province from January 2017 to December 2020. Results: The subjects' mean age was 47.87 ± 11.55 years, 52 female and 8 male (female-to-male ratio 6.5:1). About 23.3% of patients with RA had positive family history. The main comorbidities and associated diseases were hypertension (18.3%) and hypothyroidism (15%). The most frequently involved joints were the wrist, metacarpophalangeal, proximal interphalangeal, elbow, and knee joints. Subjects were positive in 66.7% for rheumatoid factor and 78.3% for anti-cyclic citrullinated peptide. Both markers were positive in 60% of the patients. Conclusion: Approximately one-quarter of the studied group had a family history of RA. Hypertension followed by hypothyroidism was the most common comorbidities reported in our study.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Profile and Comorbidities Associated with Rheumatoid Arthritis Patients in Sudair, Saudi Arabia

Alanazi

2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

show abstract

“…Indeed, csDMARDs side effects, such as mild gastrointestinal symptoms, may negatively impact quality of life and may cause loss of adherence [ 15 ]. Some factors seem to be associated with loss of efficacy, such as female sex or ethnicity, and sex differences on pharmacokinetic have been hypothesized [ 20 ]. Despite csDMARDs being the first line treatment in a previous analysis on 1287 arthritic patients, 34% of patients stopped MTX due to intolerability; therefore, the identification of risk factors associated to intolerability should be further investigated since MTX represents the anchor drug in the treatment of RA [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy

et al. 2023

View full text Add to dashboard Cite

Background Rheumatoid Arthritis (RA) is a chronic inflammatory disease with a heterogeneous treatments’ clinical response. Goals of treatment are remission and low disease activity, which are not achieved in all patients despite the introduction of early treatment and the treat to target strategy. Objective To investigate the causes of disease-modifying antirheumatic drugs (DMARDs) discontinuation and treatment failure and multiple failure for inefficacy, and to identify possible failure predictors’ according to RA patient characteristics in a real-world setting. Methods 718 RA patients were retrospectively evaluated. Conventional synthetic (cs) and biologic (b)DMARDs treatments line/s, effectiveness, and reasons of discontinuations were evaluated. Patients failing to at least two csDMARDs or bDMARDs’ drug for inefficacy were defined “csDMARDs multifailure” and “bDMARDs multifailure”, respectively. Discontinuation of at least two cs- and bDMARDs was termed “global multifailure”. Results In total, 1422 csDMARDs and 714 bDMARDs treatment were analysed. Causes of csDMARDs discontinuation were intolerance (21.8%), inefficacy (20.2%), acute adverse reactions (5.3%) and severe infections (0.6%) while csDMARDs multifailure for inefficacy was observed in 5.7% of cases. Reasons of bDMARDs withdrawal were inefficacy (29%), intolerance (10.0%), acute adverse reaction (6.3%) and severe infections (1.5%). Altogether, 8.4% of patients were bDMARDs multifailure for inefficacy while 16.6% were global multifailure. Longstanding disease (≥ 12 months) and smoke habit, resulted as positive predictor of csDMARDs failure (OR 2.6 and OR 2.7, respectively). Thyreopathy was associated with both csDMARDs failure and global multifailure (OR 2.4 and OR 1.8, respectively). Higher prevalence of failure to at least one bDMARDs and global multifailure was detected in female than male (OR 2.3 and OR 2, respectively). Conclusions Different causes of drug discontinuation were observed on DMARDs treatments. Demographic and clinical features were identified as possible predictors of both cs- and bDMARDs treatment failure and multiple failure, underlining the need of a more personalized therapeutic approach to achieve treatment targets.

show abstract

“…The Arabic MISS (Methotrexate Intolerance Severity Score) was used in this survey and statistical analyses were performed to understand associations between MTX intolerant and MTX tolerant patients. The study found that MTX intolerance was associated with the female gender (adjusted odds ratio (AOR) 6.724; 95% CI 1.420, 31.843, P = 0.016) [48]. Thus, in addition to disease activity, the patient characteristics may significantly affect MTX intolerance.…”

Section: Methotrexate: Mechanism Of Action and Intolerancementioning

confidence: 96%

Methotrexate intolerance in Rheumatoid Arthritis

et al. 2023

View full text Add to dashboard Cite

Rheumatoid Arthritis is one of the most common autoimmune diseases, causing irreversible joint damage and disability. Methotrexate (MTX) is the gold standard drug for this. The low cost, easy availability and high efficacy makes it the most important and commonly used DMARD in developing and low income countries. However, long term use of MTX is also associated with intolerance including gastrointestinal effects such as nausea, vomiting, abdominal pain and diarrhoea. In addition, anticipatory, associative and behavioural symptoms such as anxiety and irritability are also observed. These adverse effects arise as a conditioned response and are often inadequately managed, leading to discontinuation of treatment. Understanding and assessing the incidence of MTX intolerance across ethnicities and geographical regions would lead to a better treatment compliance. In this review we present a compilation of the available literature on Methotrexate intolerance in Rheumatoid Arthritis and strategies to mitigate this effect.

show abstract

<p>Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients</p>

Cited by 14 publications

References 17 publications

Clinical Profile and Comorbidities Associated with Rheumatoid Arthritis Patients in Sudair, Saudi Arabia

Clinical Profile and Comorbidities Associated with Rheumatoid Arthritis Patients in Sudair, Saudi Arabia

Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy

Methotrexate intolerance in Rheumatoid Arthritis

Contact Info

Product

Resources

About